Video

Glaukos COO shares product updates, 2021 pipeline

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|GLAUCOMA 360

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.


See more Glaucoma 360 coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
Related Content
(Image credit: AdobeStock/ipopba) Robotic precision: Elevating the state of laser cataract surgery
August 12th 2025

Robotic precision: Elevating the state of laser cataract surgery

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
August 12th 2025

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

(Image credit: AdobeStock/NicoElNino) Dialing in precision: Astigmatism management with arcuate incisions
August 12th 2025

Dialing in precision: Astigmatism management with arcuate incisions

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
August 12th 2025

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

PolyActiva enrolls first patient in phase 2b clinical trial of PA5108 ocular implant
August 12th 2025

PolyActiva enrolls first patient in phase 2b clinical trial of PA5108 ocular implant

Kowa initiates phase 3 safety trial of NCX 470 in Japan
August 12th 2025

Kowa initiates phase 3 safety trial of NCX 470 in Japan

© 2025 MJH Life Sciences

All rights reserved.